Date: 21 January 2025
BSF Enterprise and Sartorius
Sign Strategic Collaboration
to Drive Cost-Effective and
Sustainable Biotech Solutions
BSF Enterprise (BSFE), through its 3D
Bio-Tissues (3DBT) subsidiary, is transforming the biotech
landscape with innovative technologies that
include scaffold-free tissue engineered materials
and patented macromolecular crowders, used as
media additives to optimize cell growth. These chemically defined,
bio-inert additives, marketed as City-Mix™ for the alternative
protein industry and CytoBoost™ for the biopharma
industry, positively affect cell behaviour, reducing
the need for expensive growth factors or animal
serum in cell culture media. These products provide tailored
solutions for advancing cell research and production efficiency,
marking a step forward in sustainable biotechnology.
To accelerate the
impact of these technologies, 3DBT and Sartorius,
a global leader in bioprocess solutions, have entered into
a Memorandum
of Understanding (MoU). This
strategic partnership aims to leverage the combined strengths of
both companies, driving innovation and efficiency in the
development of sustainable production methods.
The collaboration will focus on
developing innovative solutions that enhance production efficiency
and sustainability, aligning with industry goals of balancing
affordability with environmental responsibility. By working
together, Sartorius and 3DBT aim to explore new technologies and
methodologies that could significantly impact the scalability and
cost-effectiveness of lab-grown leather and alternative protein
products. As part of the MoU and the partnership, Sartorius will
support 3DBT with a range of cell culture platforms, technologies,
and technical expertise to enable the joint development of a
cost-effective large-scale production of cells and tissues used in
the manufacture of 3DBT's leading lab-grown meat and leather
products over the next 12 months.
This partnership reflects a mutual
commitment to pioneering advancements in alternative protein
technology and sustainability, paving the way for future
innovations in the field. Both companies are eager to contribute
their expertise and resources to this collaborative effort, which
promises to deliver meaningful progress in the industry.
Dr. Che Connon, Managing Director of
BSF Enterprise, stated: "Partnering with Sartorius is a pivotal
moment for us. Their expertise extends beyond bioreactor
technology to encompass advanced equipment, innovative
software solutions, process optimization, and scaling up. They are
also skilled in the large-scale development and production of raw
materials, including cell culture media, growth factors, and
cytokines. Combined with our innovative
macromolecular crowder additives, this opens the door to
cost-effective, sustainable production solutions for the
alternative protein and lab-grown leather industries. This
partnership has the potential to be a game-changer in achieving
scalability at reduced costs."
Dr. Érica Schulze, Business
Development Manager at Sartorius, commented: "Sartorius excels in
developing cutting-edge products and optimizing processes across
various industries. Our commitment to sustainability drives us to
optimize resource use and minimize waste, following circular
economy principles. This dedication to innovation and sustainable
bioprocessing aligns perfectly with our partnership
goals."
About BSFE
BSF Enterprise PLC (BSF) develops and
commercialises cutting-edge tissue-engineered solutions, including
lab-grown leather, cultivated meat, and corneal repair
technologies. By leveraging its proprietary scaffold-free platform,
BSF aims to deliver sustainable alternatives to traditional
materials and meet global demand for environmentally responsible
innovations.
About Sartorius
Sartorius is a leading partner in
the biopharmaceutical industry, supporting the development and
production of biotech drugs and vaccines from lab to commercial
scale. Renowned for its state-of-the-art products and process
optimization, Sartorius have also been a trusted supplier to
the food and beverage industry for decades.
This extensive experience has sharpened our expertise, fine-tuned
our products and now put us in prime position to support
advancements in food technology and production. Particularly in the
area of novel foods where microorganisms and mammalian cells play a
crucial role, such as cultivated meats, seafood, and dairy
alternatives.
Looking Ahead
This MoU represents a significant
step toward delivering breakthrough solutions for the biotech
industry. By aligning with Sartorius, BSF is well-positioned to
drive innovation, reduce production costs, and advance
sustainability in high-growth markets.
For
further enquiries, please visit www.bsfenterprise.com or
contact:
|
BSF Enterprise PLC
|
|
|
Geoff Baker - Executive
Director
Che Connon - CEO &
Director
|
|
|
|
|
|
Shard Capital (Broker)
|
|
|
Damon Heath
Isabella Pierre
|
0207 186 9000
0207 186 9927
|
|
|
|
|
|
|
|
|
|
About BSF Enterprise PLC
BSF Enterprise PLC (BSF) is the
parent to a portfolio of innovative subsidiary companies focused on
developing and commercialising cell-based tissue engineering
solutions to deliver sustainable outcomes across a variety of
sectors. Its portfolio of subsidiaries is as follows:
3DBT A pioneering UK-based
tissue engineering company that has developed scaffold-free tissue
production processes as well as leading on the commercial use of
macromolecular crowders to transform cell culture.
Lab-Grown Leather Ltd A company
focused on the customer driven development of cultivated skin
technology to produce sustainable leather.
Kerato Ltd A tissue engineering
company with patent-protected IP that is focussing on
commercialising technologies for corneal repair with veterinary
trials starting 2025 .
BSF
Enterprise (Hong Kong) Limited A
company established to actively support commercialisation of BSF's
technology in China and Asia.
Cultured Meat Technologies (CMT) A 100% owned company, using technology developed within 3DBT,
successfully produced the UK's first high-quality cultivated meat.
Currently focused on providing the market with the premier platform
for manufacturing cultivated meat in a scalable and
cost-competitive manner.
BSF's core strategy is to acquire,
invest in, or develop joint ventures with, the most promising
companies from across the industry. In doing so BSF intends to
create an environment in which its portfolio of companies can
flourish and collaborate, thereby accelerating their progress,
potential and time to market.
